GSK2983559

GSK2983559

CAT N°: 31458
Price:

From 49.00 41.65

GSK2983559 is a receptor-interacting protein kinase 2 (RIPK2) inhibitor.{54446} It inhibits RIPK2 by 65% in a kinase assay when used at a concentration of 10 µM. GSK2983559 (10 µM) also inhibits VEGFR3 by greater than 90%, as well as 14 additional kinases by 60 to 89% in a panel of 344 kinases. In vivo, GSK2983559 (7.5 and 145 mg/kg twice per day) reduces colonic damage in a mouse model of TNBS-induced colitis. GSK2983559 is also a prodrug that is cleaved to an active metabolite in the gastrointestinal tract that inhibits RIPK2 more potently than GSK2983559.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-[[4-(5-benzothiazolylamino)-6-[(1,1-dimethylethyl)sulfonyl]-7-quinazolinyl]oxy]-ethanol, 1-(dihydrogen phosphate)
  • Correlated keywords
    • GSK-2983559 RIPK 2 VEGFR 3 pro-drug
  • Product Overview:
    GSK2983559 is a receptor-interacting protein kinase 2 (RIPK2) inhibitor.{54446} It inhibits RIPK2 by 65% in a kinase assay when used at a concentration of 10 µM. GSK2983559 (10 µM) also inhibits VEGFR3 by greater than 90%, as well as 14 additional kinases by 60 to 89% in a panel of 344 kinases. In vivo, GSK2983559 (7.5 and 145 mg/kg twice per day) reduces colonic damage in a mouse model of TNBS-induced colitis. GSK2983559 is also a prodrug that is cleaved to an active metabolite in the gastrointestinal tract that inhibits RIPK2 more potently than GSK2983559.

We also advise you